Gabexate mesilate is a synthetic protease inhibitor that is effective for acute pancreatitis. The effect of gabexate mesilate in influenza pneumonia in mice was investigated by examining the changes in pulmonary inflammatory cytokines and chemokines. Pathological changes in the lungs of treated mice were extremely mild, compared with changes in infected, untreated mice. Intrapulmonary levels of interleukin-6 and macrophage inflammatory protein-2 decreased in treated mice compared with untreated mice, despite similar viral titres in the lungs. Survival terms for treated and untreated groups were similar. These data indicate that gabexate mesilate has beneficial effects on influenza pneumonia, which may be due to the modulation of inflammatory cytokine/chemokine responses.
Introduction
Globally, influenza virus is a major cause of respiratory disease and pneumonia is one of the most important complications associated with this infection. 1 -5 The pathogenicity of the influenza virus is determined by the genetic polymorphism of virus subtypes and host cellular factors that regulate virus entry into target cells. 3, 6 Cleavage of the influenza virus envelope glycoprotein precursor, haemagglutinin -which induces the fusion activity of the virus and allows the viral genome to enter the cytoplasm -occurs extracellularly in the membranes of airway epithelial cells and/or in the airway fluid, by the proteolytic enzymes. 6 -8 The activity of the processing protease is regulated by endogenous host defence compounds in the airway, such as mucus protease inhibitor in the upper respiratory tract and pulmonary surfactant in the lower respiratory tract. 9, 10 In addition, cytokines and other immune molecules are reported to be associated with the pathogenicity of severe influenzaassociated pneumonia. An earlier study described fulminant pathological changes in the lungs of mice inoculated with influenza virus followed by Streptococcus pneumoniae infection 2 days later, and several critical immune responses (such as cytokine and chemokine release, and toll-like receptor [TLR] expression) were increased. 11 K Kosai, M Seki, K Yanagihara et al.
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Furthermore, chronic Pseudomonas aeruginosa infection in mice is exacerbated by the influenza virus, while decreased neutrophil function due to viral infection might induce the lethal pneumococcal pneumonia observed in such mice. 12 These results suggest that specific immunological reactions by cytokines and neutrophil enzymes mediate such severe pneumoniarelated influenza virus infections. Tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6) and macrophage inflammatory protein (MIP)-2 were used to monitor the immune response in this study.
Gabexate mesilate is a synthetic serine protease inhibitor that inhibits trypsin, plasmin, kallikrein and thrombin. 13 Consequently, it has been used to treat acute pancreatic and disseminated intravascular coagulation, and as an anticoagulant during haemodialysis. 14 -16 The drug also suppresses other inflammatory mediators, including cytokines, oxygen-derived free radicals and leucocyte adhesion molecules, and has favourable effects on hepatic and pulmonary injury. 17, 18 The present study evaluated the effects of gabexate mesilate on influenza pneumonia in mice, in an attempt to reduce lung injury and explore the possible clinical application of this drug for influenza infection.
Materials and methods

ANIMALS
Six-week-old male CBA/J mice (specific pathogen-free) were used for this evaluation. Each of the treatment and control groups were housed in isolation from each other following influenza inoculation. The study was approved by the ethical committee of Nagasaki University.
MATERIALS
A mouse-adapted A-strain influenza virus (strain A/PR8/34: H1N1 type), kindly provided by Prof. Nobuyuki Kobayashi, Department of Pharmaceutical Science, Nagasaki University, Japan, was used to inoculate selected mice, as reported previously. 11 Gabexate mesilate (FOY ® ) was kindly provided by Ono Pharmaceutical Company, Osaka, Japan. Immediately before use, the gabexate mesilate was dissolved in saline and filtered through a 0.22 µm pore membrane for sterilization.
EXPERIMENTAL GROUPS AND TREATMENTS
The mice were divided randomly into three groups each comprising six mice. Two of these groups were intranasally inoculated with 50 µl of A-strain influenza virus (1 × 10 4 plaque-forming units [pfu]/ml). One of these groups received the influenza virus inoculation only whereas the other group was then treated with gabexate mesilate (5 mg/kg, intraperitoneally). The third group was a control that was given intranasal saline instead of influenza virus and was then treated with gabexate mesilate (5 mg/kg, intraperitoneally).
HISTOLOGICAL ANALYSIS
The mice were sacrificed 48 h after influenza virus inoculation and the lungs were collected as samples, as described previously. 11 Paraffin embedding and tissue staining with haematoxylin and eosin were performed using standard methodologies.
VIRAL PREPARATION AND TITRES
Madin-Darby canine kidney cells were used for the maintenance of influenza virus, and the plaque formation assay was used to analyse viral titres in Dulbecco's modified Eagle's medium (Gibco BRL, Gaithersburg, MD, USA). Influenza virus was cultured in these cells for several days and supernatants K Kosai, M Seki, K Yanagihara et al.
Effects of gabexate mesilate in influenza
were collected and stored at -80°C as viral stocks until use in the experiments.
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
Concentrations of TNF-α, IL-6 and MIP-2 in aqueous lung extracts were assayed by ELISA using mouse Quantikine kits (R&D Systems, Minneapolis, MN, USA). To prepare aqueous lung extracts, homogenates were centrifuged for 60 min at 2 000 g at 4°C. Supernatants were collected and used in the assays.
STATISTICAL ANALYSIS
All data were expressed as means ± SD and were analysed using StatView ® software (Abacus Concepts, Cary, NC, USA). Differences between groups were examined for significance using an unpaired t-test. Pvalues < 0.05 were considered to indicate statistical significance. 1D ). Pathological examination of the lungs of influenza-infected mice showed severe bronchopneumonia ( Figs 1B and 1E ) on day 2 post-inoculation, whereas the lungs of mice inoculated with influenza and treated with gabexate mesilate exhibited only moderate pneumonia ( Figs 1C and 1F) . The untreated lungs were filled with inflammatory cells and almost the entire airspace was obliterated. In contrast, pulmonary invasion of inflammatory cells was mild in gabexate mesilate treated mice.
Results
SEVERE PNEUMONIA IN CO-INFECTED MICE
Pneumonia-infected mice started to die from day 3 following virus inoculation and, by day 14, all mice had died. There was no 
VIRAL TITRES IN LUNGS OF INFLUENZA-INFECTED MICE
Changes in the viral titres in the lungs of mice at 48 h post influenza virus inoculation were analysed. Results of the plaque formation assay showed almost the same influenza viral titres in the lungs of mice treated with gabexate mesilate and in those of the untreated mice (Fig. 2 ).
EFFECT OF INFECTION TYPE ON PULMONARY INFLAMMATORY CYTOKINES
As shown in Fig. 3 , intrapulmonary levels of IL-6 and MIP-2 decreased significantly in the lungs of mice treated with gabexate mesilate, as compared with untreated mice. However, TNF-α levels did not change after gabexate mesilate treatment (data not shown).
Discussion
In the present study, a mouse model of influenza pneumonia was treated with gabexate mesilate. Significantly milder bronchitis and decreased inflammatory cytokines were observed in treated influenzainfected mice, compared with those given no treatment: the latter exhibited severe bronchopneumonia and increased inflammatory cytokines. On microbiological analysis, titres of influenza virus in the lungs of gabexate mesilate-treated mice were almost the same as titres in the lungs of untreated mice. These data suggest that gabexate mesilate does not inhibit influenza pneumonia by blocking the cleavage of K Kosai, M Seki, K Yanagihara et al.
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influenza virus haemagglutinin, the activity of which is strictly regulated by specific enzymes. 3, 6 The influenza-infected mice gradually started to die from day 3 following virus inoculation and all mice had died by day 14, which accords with previous data from Seki et al. 11 Although significantly longer survival in treated mice was not seen, the present results revealed decreases in intrapulmonary cytokine/chemokine concentrations in influenza pneumonia after gabexate mesilate treatment. The concentrations of IL-6 and MIP-2 (which is functionally similar to IL-8 in humans) decreased significantly in the lungs of treated mice compared with untreated mice infected with influenza, although there was no change in TNF-α concentrations. The host immune response is one of the most important factors in determining lung pathology in influenza and gabexate mesilate may affect influenza pneumonia as an immunological modulator.
In vivo studies have demonstrated that gabexate mesilate prevents acute necrotizing pancreatitis in rats and ischaemia/ reperfusion injury in canine kidney autoplantation. 14, 19 These effects are thought to be mediated via immunological reactions, including the inhibition of cytokine secretion and apoptotic pathways. Moreover, in clinical trials, gabexate mesilate improved mortality and morbidity in acute pancreatitis patients and prevented the development to pancreatitis after endoscopic retrograde cholangio-pancreatography; 15 -20 the drug significantly ameliorated abdominal pain, hyperamylasaemia and leucocytosis in these patients. 15 -20 Leucocytes, particularly neutrophils, are considered to be key immune cells against infection; through cytokine/chemokine secretion, they are thought to modulate the risk of subsequent bacterial pneumonia. 12 Neutrophils are central to the control of infection within the bronchial mucosa, and decreased severity of inflammation in the respiratory tract can be partly explained by acute reductions in neutrophil function. Further studies on neutrophil function in influenza-infected mice treated with gabexate mesilate are, therefore, needed.
In conclusion, treatment of influenza pneumonia by gabexate mesilate administration reduced the onset of severe pneumonia in our murine model. These pathological changes may be regulated by host immune responses, including cytokine/chemokine secretion. Gabexate mesilate administration may protect against severe inflammation and improve symptoms in influenza patients. Further studies are necessary in order to establish the clinical effectiveness of gabexate mesilate for influenza infection.
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